- Home
- FBRX vs LAB Comparison
FBRX vs LAB Comparison
Compare FBRX & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRX | LAB |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | 389 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.2M | 394.3M |
| IPO Year | 2017 | 2008 |
Fundamental Metrics
Financial Performance| Metric | FBRX | LAB |
|---|---|---|
| Price | $22.25 | $1.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $67.00 | $1.35 |
| AVG Volume (30 Days) | 194.1K | ★ 2.0M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.30 | ★ 61.54 |
| EPS | N/A | ★ 0.33 |
| Revenue | $36,000.00 | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | ★ N/A | $3.18 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.78 | $0.87 |
| 52 Week High | $35.80 | $1.72 |
Technical Indicators
Market Signals| Indicator | FBRX | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 60.02 |
| Support Level | $10.38 | $0.92 |
| Resistance Level | $22.61 | $1.38 |
| Average True Range (ATR) | 2.22 | 0.05 |
| MACD | -0.51 | 0.01 |
| Stochastic Oscillator | 27.81 | 81.19 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.